AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT01004510
Drug: zoledronic acid
RxNorm normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Zoledronic acid (Zometa) 4mg IV every 4 weeks for 3 treatments with chemotherapy as selected by treating physician
Trial: NCT00382083
Drug: 1000 mg acetaminophen
RxNorm normalized name: acetaminophen 1000 MG
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00382083
Drug: 800 mg ibuprofen
RxNorm normalized name: ibuprofen 800 MG
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT02818686
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00002531
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT01142726
Drug: Methotrexate placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablets, oral, to match 2.5-mg tablet, once weekly, 12 months
Trial: NCT02125981
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: taking placebo drug
Trial: NCT00002531
Drug: doxorubicin hydrochloride
RxNorm normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00002531
Drug: leucovorin calcium
RxNorm normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00002531
Drug: mercaptopurine
RxNorm normalized name: Mercaptopurine
DrugBank: Mercaptopurine (DB01033)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00002531
Drug: methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00002531
Drug: prednisolone
RxNorm normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT03354611
Drug: Contrast Dye, Iodinated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.5-2ml/kg body weight (100 ml maximum) of a low osmolar, nonionic, 300-350 mgI/ml iodinated contrast agent, will be injected at a rate of \~2.0 ml/s, for a total injection time of 30-60 seconds (for a 50 kg subject). This will be immediately followed by a saline chaser from 20 to 40 ml at \~2 ml/s (20 seconds) to maximize dynamic enhancement.
Trial: NCT04079101
Drug: BIIB104
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered as specified in the treatment arm.
Trial: NCT04079101
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered as specified in the treatment arm.
Trial: NCT01751854
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo alone or with training
Trial: NCT00243347
Drug: AZD2171
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral tablet
Trial: NCT02495168
Drug: Symbicort® (Budesonide/Formoterol Fumarate Dihydrate)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral inhalation, brand-name product.
Trial: NCT02495168
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral inhalation, no active ingredient.
Trial: NCT00133952
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered orally
Trial: NCT00464763
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04613167
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The third group will receive only optimal guidelines-based secondary preventive treatment. Blood samples from all patients will be drawn for laboratory measurements and genetics determination. Ultrasound measurement of endothelium-dependent dilatation of the brachial artery, intima media thickness of carotid arteries and pulse wave will be measured.
Trial: NCT03146533
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: patients will receive a standard pre-conditioning regime with cyclophosphamide 0.8g/m2/day IV for 2 days.
Trial: NCT02665286
Drug: Naproxen
RxNorm normalized name: Naproxen
DrugBank: Naproxen (DB00788)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Naproxen 500mg PO BID x 7 days
Trial: NCT02665286
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1/2 of placebo packages will be dosed to match methocarbamol: 1-2 tabs po TID x 7days 1/2 of placebo packages will be dosed to match orphenadrine: 1 tab PO BID x 7 days
Trial: NCT02940444
Drug: Heparin
RxNorm normalized name: Heparin
DrugBank: Heparin (DB01109)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01206803
Drug: Ovarian stimulation in a GnRH-antagonist protocol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Long-acting FSH 150µg \& daily recombinant FSH 200 IU, GnRH-antagonist 0.25mg, 5,000-10,000 IU urinary hCG, triptorelin 0.2mg, vaginal progesterone
Trial: NCT04695041
Drug: PBI-4050/ Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants receive either 800mg PBI-4050 capsules or placebo, twice a day for 14 days
Trial: NCT04695041
Drug: PBI-4050/ Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants receive either 1000 mg PBI-4050 capsules or placebo, twice a day for 14 days
Trial: NCT04695041
Drug: PBI-4050/ Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants receive either 1200 mg PBI-4050 capsules or placebo, twice a day for 14 days
Trial: NCT04695041
Drug: PBI-4050/ Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants receive either 800 mg PBI-4050 capsules or placebo, three times a day for 14 days
Trial: NCT02814019
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00308906
Drug: aminoglycoside
RxNorm normalized name: Aminoglycoside
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aminoglycosides will be administered and monitored as part of the routine standard of care for the subject.
Trial: NCT02305134
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02770690
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: apply normal saline before propofol iv injection
Trial: NCT02411136
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multiple doses of AMG 623 administered as subcutaneous and intravenous doses
Trial: NCT00848354
Drug: Phase 1: Methotrexate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phase 1: oral tablet, 2.5mg, dose variable from 7.5mg to 25mg, once weekly for study weeks 0 - 24.
Trial: NCT00848354
Drug: Phase 2: Optional ETN, SSZ, HCQ, MTX
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phase 2: All therapies are optional and may include any combination of the following: ETN, SSZ, HCQ, MTX Phase 2: Optional ETN: prefilled syringe 50mg/ml, dose variable after study week 24 to week 128.~Phase 2: Optional SSZ: oral tablet, 0.5gm, dose variable per approved local label recommendations after study week 24 to week 128.~Phase 2: HCQ: oral tablet, 200mg, dose variable per approved local label recommendations after study week 24 to week 128.~Phase 2: MTX: oral tablet, 2.5mg dose variable after week 24 to week 128.
Trial: NCT00848354
Drug: Phase 1: Methotrexate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phase 1: oral tablet, 2.5mg dose variable from 7.5mg to 25mg, once weekly for study weeks 0 - 24.
Trial: NCT00848354
Drug: Phase 1: Conventiaonal DMARD
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phase 1: SSZ: oral tablet, 0.5gm, dose variable per approved local label recommendations. OR Phase 1: HCQ: oral tablet, 200mg, dose variable per approved local label recommendations.
Trial: NCT06365398
Drug: Heparin
RxNorm normalized name: Heparin
DrugBank: Heparin (DB01109)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: As soon as the sheath was inserted, three different doses of heparin were administered according to the patients group assignment. In the conventional systemic heparinization (Regular-dose) group (The drug is Heparin Sodium Injection 2ml:12500 Units per bottle), systemic heparin was administered by intravenous injection at a dose of 83 Units/Kg. Patients in both the regular dose (83 units/kg) and low dose (42 units/kg) groups were given heparin intravenously once before the procedure of cerebral angiography, and no further heparin infusion was given during the angiography procedure. If the duration of the imaging procedure exceeded 1 hour, an additional 1/2 amount of the first dose of heparin was given.
Trial: NCT02604940
Drug: Normal Saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 60ml Saline delivered over 10 minutes in OR upon notification of surgical closure.
Trial: NCT04643691
Drug: Losartan 50 mg and Spironolactone 25 mg pillules oral use
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Losartan 50 mg and Spironolactone 25 mg pillules oral use during 10 days
Trial: NCT00660660
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: once daily
Trial: NCT02645253
Drug: AZD7594 inhalation powder (200 μg)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 μg AZD7594 inhalation powder via multi-dose dry powder inhaler (DPI)
Trial: NCT02645253
Drug: AZD7594 inhalation powder (400 μg)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cohort 2: 400 μg AZD7594 inhalation powder via multi-dose DPI Cohort 3: 1600 μg (4 x 400 μg inhalations) AZD7594 inhalation powder via multi-dose DPI
Trial: NCT02645253
Drug: AZD7594 pressurized inhalation suspension (200 μg)
RxNorm normalized name: penicillin G Injectable Suspension
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400 μg (2 x 200 μg inhalations) AZD7594 pressurized inhalation suspension via pressurized metered dose inhaler (pMDI)
Trial: NCT02645253
Drug: AZD7594 placebo inhalation powder
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AZD7594 placebo inhalation powder via multi-dose DPI
Trial: NCT06365398
Drug: Heparin Sodium Injection
RxNorm normalized name: Heparin Sodium Injection
DrugBank: Heparin (DB01109)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: In the micro-dose systemic heparinization (Micro-dose) group (the drug is Heparin Sodium Injection 2ml:12500 Units per bottle), systemic heparin was administered by intravenous injection at a dose of 42 Units/Kg. Patients in both the regular dose (83 units/kg) and low dose (42 units/kg) groups were given heparin intravenously once before the procedure of cerebral angiography, and no further heparin infusion was given during the angiography procedure. If the duration of the imaging procedure exceeded 1 hour, an additional 1/2 amount of the first dose of heparin was given.
Trial: NCT00486187
Drug: metformin or sulfonylurea
RxNorm normalized name: metformin and sulfonylureas
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04365387
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo will be administered by 2 SC injections at baseline and a single dose at Weeks 4, 8, and 12.
Trial: NCT02853604
Drug: ADXS11-001
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02853604
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04161898
Drug: Prednisolone
RxNorm normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Prednisolone will be administered as oral tablet
Trial: NCT00975494
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03434275
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once Daily
Trial: NCT02039492
Drug: Treatment with aldactone
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02221947
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo, single dose via intravenous infusion over 1 hour.
Trial: NCT01539538
Drug: Sufentanil NanoTab PCA System/15 mcg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15 mcg Sufentanil NanoTab dosed sublingually q 20 minutes as needed for pain for at least 48 hours and up to 72 hours
Trial: NCT01654484
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ophthalmic Solution, QD, 28 days
Trial: NCT02045667
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo tablets do not contain any active medicinal component.
Trial: NCT01260805
Drug: Reference Drug
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Femiane® Ethinylestradiol 0,02mg + Gestodene 0,075mg sugar coated tablets single dose
Trial: NCT01260805
Drug: Test Drug
RxNorm normalized name: URINE TEST DRUGS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Harmonet® Ethinylestradiol 0,02mg + Gestodene 0,075mg sugar coated tablets single dose
Trial: NCT00081653
Drug: ibandronate [Bonviva/Boniva]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 150mg po monthly for 3 years
Trial: NCT00081653
Drug: ibandronate [Bonviva/Boniva]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100mg po monthly for 3 years
Trial: NCT03548194
Drug: BNC210
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BNC210 300 mg b.i.d
Trial: NCT03548194
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo b.i.d.
Trial: NCT02179294
Drug: Remifentanil
RxNorm normalized name: Remifentanil
DrugBank: Remifentanil (DB00899)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dedicated intravenous cannula for remifentanil administration PCA protocol~* PCA bolus remifentanil 40 μg~* Lockout interval 2 minutes~In the event of excess sedation being recorded by regular observation of respiratory function, the regimen will be altered by reduction of the remifentanil bolus dose to 30 μg with a lock-out interval of 2 minutes.
Trial: NCT03222960
Drug: propolis-containing toothpaste
FDA approved: no
EMA approved: no
PMDA approved: no
Description: participants will use propolis-containing toothpaste for 6 months
Trial: NCT03222960
Drug: Fluoride-containing toothpaste
FDA approved: no
EMA approved: no
PMDA approved: no
Description: participants will use Fluoride-containing toothpaste for 6 months
Trial: NCT00868660
Drug: ZP1848
FDA approved: no
EMA approved: no
PMDA approved: no
Description: sc. bolus
Trial: NCT02741687
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will take one pill daily beginning on the day prior to surgery and continuing through hospitalization, up to 10 days.
Trial: NCT02241629
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo of levo phencynonate hydrochloride
Trial: NCT04464629
Drug: Prednisolone Acetate
RxNorm normalized name: Prednisolone Acetate
DrugBank: Prednisolone acetate (DB15566)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Topical Prednisolone acetate 1% ophthalmic suspension
Trial: NCT00134082
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 50 mg/kg/day on Day -3, -2, -1, and 0.
Trial: NCT02279563
Drug: Dymista™ Nasal Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02279563
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01592240
Drug: 300mg PF-04950615 (RN316)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PF-04950615 300 mg, Q28d
Trial: NCT04492280
Drug: Hydrocortisone
RxNorm normalized name: Hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: After approval of the ethical committee of faculty of Medicine Ain Shams University and obtaining a written informed consent from all patients or their legal guardians, the study will be conducted on 66 patients subdivided randomly via computer closed envelopes method into 3 equal groups, 22 patients for each group; group HF (hydrocortisone \& fludrocortisone), group H (hydrocortisone) and group C (control group).
Trial: NCT02042183
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0 mcg soft capsules of placebo for oral administration
Trial: NCT02256189
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo one tablet daily
Trial: NCT00378378
Drug: Placebo nasal spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One spray of placebo nasal spray in each nostril once daily for 4 months.
Trial: NCT00003955
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT02454491
Drug: Heparin
RxNorm normalized name: Heparin
DrugBank: Heparin (DB01109)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: intraradial administration of heparin 5000 ui
Trial: NCT01746745
Drug: [^14C]-LY2940680
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered as solution by mouth
Trial: NCT03711903
Drug: Acetyl-Valine-Serine-Arginine-Arginine-Arginine-NH2 (Ac-VSRRR- NH2).
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The study drug, CN-105 is supplied in amber glass vials containing 4 mL of a concentrated 12.5-mg/mL clear-to-slightly-yellow solution.
Trial: NCT00802139
Drug: venoferrum(iron sucrose)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: administer once weekly calculated quantity of Venoferrum® ampoules according to body weight and Hb level.
Trial: NCT03183076
Drug: Pharmacotherapy without diet
RxNorm normalized name: phentermine hydrochloride Oral Capsule [T-Diet]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients were assigned to two groups, one of them received conventional treatment with antiepileptic drugs without a special diet
Trial: NCT00601458
Drug: naproxen sodium
RxNorm normalized name: Naproxen Sodium
DrugBank: Naproxen (DB00788)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients will be randomized just prior to surgery to 1 of 3 study treatments: naproxen sodium (550 mg) treatment will be administered approximately 1 hour prior to surgery. Postoperatively, naproxen sodium will be dosed starting 12 hours following T=0 and every 12 hours until 36 hours following T=0.
Trial: NCT00601458
Drug: Comparator: Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will be randomized just prior to surgery to 1 of 3 study treatments: placebo treatment will be administered approximately 1 hour prior to surgery. Postoperatively, placebo will be dosed starting at 8 hours following T=0 and every 8 hours until 40 hours following T=0.
Trial: NCT00729651
Drug: Comparator: Alendronate sodium (Fosamax)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alendronate sodium; tablet, once weekly, for 16 weeks
Trial: NCT03129100
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered SC
Trial: NCT01145066
Drug: borage/echium oil combination
FDA approved: no
EMA approved: no
PMDA approved: no
Description: borage/echium oil combination containing 0.85g/day SDA and 1.7g/day GLA
Trial: NCT01774968
Drug: Human Regular U-500 Insulin
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01648101
Drug: Retigabine 900mg/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Study drug will be administered three times a day in a double blind manner. The starting dose of retigabine will be 300 mg/day. This dose will be increased by 150 mg/day per week to reach the target dose of 900mg/day over a 4 week Titration Phase). The subject will then continue to receive 900mg/day for the next 12 weeks (Maintenance Phase). Eligible subjects will then be offered an opportunity to enter an open label extension (OLE) study. After a 4 week transition phase, eligible subjects will start the OLE on retigabine 900mg/day.
Trial: NCT01648101
Drug: Retigabine 600mg/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Study drug will be administered three times a day in a double blind manner. The starting dose of retigabine will be 300mg/day. This dose will be increased by 150 mg/day per week to reach the target dose of 600mg/day over 2 weeks. The subject will then continue to receive 600mg/day for the next 14 weeks (2 weeks of the Titration Phase and 12 weeks of the Maintenance Phase). Eligible subjects will then be offered an opportunity to enter an open label extension (OLE) study. After a 4 week Transition Phase (3 weeks on retigabine 600mg/day, 1 week on retigabine 750mg/day) eligible subjects will start the OLE on retigabine 900mg/day.
Trial: NCT04474405
Drug: Florbetapir F 18
RxNorm normalized name: Florbetapir F 18
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV injection, 370 MBq (10 mCi), single dose
Trial: NCT03636932
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous injection of 2 gram of Placebo during 4 weeks, 3 times per week during the first three hours of dialysis.
Trial: NCT03889639
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmaceutical form: Film coated tablet; Route of administration: Oral
Trial: NCT03889639
Drug: Locally approved intravenous contrast medium for contrast enhanced magnetic resonance imaging (MRI)
RxNorm normalized name: Contrased
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmaceutical form: Solution for injection; Route of administration: Intravenous
Trial: NCT03491410
Drug: Placebo Oral Tablet
RxNorm normalized name: placebo ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo is to be added in the standard patient´s treatment
Trial: NCT01535222
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Commercially available NaCl
Trial: NCT00569569
Drug: juxtascleral depot injection of Retaane
RxNorm normalized name: purified protein derivative of tuberculin Injectable Solution [Aplisol]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: juxtascleral depot injection of Retaane
Trial: NCT02269358
Drug: METHOTREXATE
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Infliximab therapy after escalation. SC methotrexate at 15 mg/m2 , not to exceed 25 mg/m2 per week for 4 weeks. Patients in remission after 4 weeks reduce their dose by halve. patients not in remission will continue the full dose until 12 weeks.